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Abstract
Background: Drug resistance testing is mandatory in antiretroviral therapy in human immunodeficiency virus (HIV)
infected patients for successful treatment. The emergence of resistances against antiretroviral agents remains the
major obstacle in inhibition of viral replication and thus to control infection. Due to the high mutation rate the virus is
able to adapt rapidly under drug pressure leading to the evolution of resistant variants and finally to therapy failure.
Results: We developed a web service for drug resistance prediction of commonly used drugs in antiretroviral
therapy, i.e., protease inhibitors (PIs), reverse transcriptase inhibitors (NRTIs and NNRTIs), and integrase inhibitors (INIs),
but also for the novel drug class of maturation inhibitors. Furthermore, co-receptor tropism (CCR5 or CXCR4) can be
predicted as well, which is essential for treatment with entry inhibitors, such as Maraviroc. Currently, SHIVA provides
24 prediction models for several drug classes. SHIVA can be used with single RNA/DNA or amino acid sequences, but
also with large amounts of next-generation sequencing data and allows prediction of a user specified selection of
drugs simultaneously. Prediction results are provided as clinical reports which are sent via email to the user.
Conclusions: SHIVA represents a novel high performing alternative for hitherto developed drug resistance testing
approaches able to process data derived from next-generation sequencing technologies. SHIVA is publicly available
via a user-friendly web interface.
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Background
Successful antiretroviral therapy (ART) in HIV infected
patients strongly depends on the effective suppression of
viral replication. Although a broad range of antiretrovi-
ral drugs have been approved by the FDA, long-lasting
reduction of virus load is still challenging today. The high
mutation rate of the virus under drug pressure remains
the major concern in ART. In general, three drugs of dif-
ferent drug classes, e.g., protease inhibitors (PIs), reverse
transcriptase inhibitors (NRTIs and NNRTIs), or entry
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inhibitors, are administered to the patient in a combined
therapy. However, as an adaption process the virus is
able to evade ART regimes finally leading to therapy fail-
ure. Therefore, predicting drug resistances or co-receptor
usage, respectively, is an essential procedure in the effi-
cient suppression of virus load and though in prolonging
a patient’s life. Overall, six drug classes are at present
available that target diverse stages within the replica-
tion cycle of HI viruses. Nucleotide reverse transcriptase
inhibitors (NRTIs) and non-nucleoside reverse transcrip-
tase inhibitors (NNRTIs) are able to block the activity of
the reverse transcriptase therewith disrupting the build-
ing process of viral DNA, which finally leads to the inhi-
bition of the virus’ life cycle. Protease inhibitors (PIs)
suppress the function of the protease enzyme, which is
responsible for cutting the gag polypeptide into functional
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proteins. Integrase inhibitors (INIs) prevent the insertion
of viral DNA into the host cell by inhibiting the viral
integrase. Another prevention of virus replication can
be achieved by inhibiting the entry of viruses into host
cells. In general, the HI virus binds to the CD4 recep-
tor of CD4 expressing cells, and additionally, to one of
two co-receptors, either CXCR4 or CCR5. The engage-
ment is crucial to activate the fusion of virus and host
cell [1]. Entry-inhibitors, such as Maraviroc [2], are able
to block the co-receptor binding to CCR5 and therefore
inhibit virus replication. However, before administering
entry-inhibitors to the patient it is necessary to predict co-
receptor usage of the viral population, as entry-inhibitors
are only effective against CCR5-tropic viruses. A rather
new antiretroviral drug, Bevirimat (BVM) [3], has been
evaluated for HIV therapy, albeit not yet approved by
the FDA for clinical application. BVM is a maturation
inhibitor that inhibits the maturation of HIV particles
to infectious virions by preventing the final cleavage
of the precursor protein p25 to p24 and p2. However,
the emergence of drug resistances is the major impedi-
ment in effective ART. Thus, sophisticated computational
algorithms have been developed to predict drug resis-
tances on viral sequences. For example, geno2pheno [4, 5],
HIVdb [6], and WebPSSM [7] are the most popular
tools in resistance testing and co-receptor tropism pre-
diction. However, there is still the great need to further
improve prediction algorithms for HIV drug resistance
and tropism prediction. For example, Dybowski et al.
[8] have shown the potential of random forest [9] mod-
els on HIV tropism prediction, outperforming prediction
performances of geno2pheno and other methods.
We developed a web service for HIV drug resistance
prediction incorporating models for resistance testing of
PIs, NNRTIs, NRTIs, INIs, BVM, as well as co-receptor
tropism prediction. The algorithm design is able to handle
up to several million sequences therefore allowing queries
with next-generation sequencing (NGS) data [10]. Predic-
tion results are provided as clinical reports presenting the
results in a comprehensible and clearly presented way and
sent via email to the user. Additionally, a data file contain-
ing resistance information for each sequence is generated
thus providing also detailed information for all sequences
within a patient. The graphical user interface makes the
application handy for researchers as well as for clinicians.
The application SHIVA is available as a web interface with
public access at http://shiva.heiderlab.de.
Implementation
The web application is based on the JAVA framework
Vaadin (https://vaadin.com) and can be accessed
via a web browser. Drug resistance models that are
incorporated into and provided by SHIVA were
implemented in R (http://www.r-project.org), thus
requiring communication and data transfer between
JAVA and R, which is handled using the Rserve pack-
age. The analytical report generation is conducted using
the JasperReports library. For processing biological
data, e.g., for translating RNA sequences into protein
sequences, the BioJava library [11] is used.
The models that were incorporated into SHIVA
so far provide predictions for six antiretroviral
drug classes comprising the following 23 drugs: PIs
(Amprenavir, Atazanavir, Indinavir, Lopinavir, Ritonavir,
Saquinavir, Nelfinavir, Darunavir), NRTIs (Lamivudine,
Abacavir, Zidovudine, Didanosine, Tenofovir, Stavudine,
Emtricitabine), NNRTIs (Efavirenz, Nevirapine,
Delavirdine, Rilpivirine), INIs (Dolutegravir, Elvitegravir,
Raltegravir), and the maturation inhibitor Bevirimat.
Furthermore, a prediction model for co-receptor tropism
prediction has been incorporated. For most of the drugs
(except Darunavir, Emtricitabine, and the INIs) resis-
tance prediction is performed by random forests models
developed in our group recently [12, 13]. These models
are based on independent binary classification for each
drug, predicting sequences as resistant or susceptible
using a drug-specific cutoff (see [12, 13]). The ran-
dom forests have been trained with 500 trees and have
been evaluated with a leave-one-out cross-validation
scheme.
Random forests [9] are ensemble learning methods
for classification and regression, consisting of mul-
tiple decision trees, which predict the drug resis-
tance for a given sequence independently of each
other. The predictions are then combined via major-
ity voting to get a final decision, i.e., resistant or
susceptible.
For feature representation, sequences were translated
to numerical values using the hydrophobicity scores
according to Kyte and Doolittle [14]. Due to varieties
in sequence lengths, an interpolation of input sequences
was conducted with Interpol [15] to vectors of lengths
99 for PIs and 240 for NNRTIs and NRTIs, respec-
tively. Feature length of p2 sequences for BVM pre-
diction was interpolated to 20. For the prediction of
co-receptor usage, we incorporated TCUP 2.0 [16] into
SHIVA, which is based on a stacking approach of two
random forest models. One random forest model is
trained on the numerical representation of the V3 loop
using hydrophobicity values, the other one is trained
on the electrostatic potential of the V3 loop. Inde-
pendent predictions are then combined via stacking
to get the final prediction result for each sequence.
Besides using data-driven approaches for drug resis-
tance, we also employed knowledge-based approaches
for the INIs, Emtricitabine, and Darunavir based on the
2015 edition of the IAS-USA drug resistance mutations
list [17].
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Results and discussion
The web application SHIVA (Fig. 1) has been developed
to provide researchers and clinicians an easy-to-use inter-
face to our recently developed drug resistance and tropism
prediction models. At the moment, there are drug resis-
tance models for 23 drugs (PIs, NRTIs, NNRTIs, INIs,
and BVM) available. Moreover, it can be used to pre-
dict co-receptor tropism based on V3 loop sequence data.
Data input must be provided as RNA/DNA or protein
sequences in FASTA format. RNA/DNA sequences are
translated into amino acid representations. Additionally,
sequences are checked for input format and illegal char-
acters. To provide the appropriate input format for the
prediction models, the protein sequences are encoded
with hydrophobicity values. For co-receptor usage predic-
tion, the electrostatic potentials of the V3 loop sequences
are calculated by TCUP 2.0 [16]. For each prediction query
the false positive rate can be controlled by setting a cut-off
for the specificity. The default value is 0.95 for drug resis-
tance predictions and 0.98 for co-receptor determination.
Figure 2 demonstrates the resistance testing workflow.
The results of the predictions are provided as clinical
reports in the web browser and can be optionally sent
via email to the user. These reports contain the following
information:
1. user information, such as user ID, a patient’s ID (if
provided), and date of query,
2. information about input data, i.e., number of
sequences, the type of sequence (RNA/DNA or
protein), and the list of sequences (only when a small
set of sequences has been queried),
3. prediction results, i.e., the prediction results for
queried drugs, the selected specificity cut-off and a
visualization for easy interpretation of prediction
results (see Fig. 3).
The clinical report shows the fraction of resistant
sequences for a given patient, which can be used to detect
resistant minority variants. Moreover, the report gives
information about the drug model used and its general
sensitivity for the selected specificity cut-off. For instance,
as shown in Fig. 3, the sensitivity of the model predicting
Ritonavir resistance is 94.02 % for the selected specificity
of 95.0 %, and the fraction of resistant sequences for the
given patient is 48.61 %.
Fig. 1Web interface of SHIVA: Sequences can be pasted directly into the input form or uploaded as FASTA files. Drugs can be selected via
checkboxes. The specificity cut-off can be selected as 0.9, 0.95, or 0.98
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Fig. 2Workflow of drug resistance prediction: First, protein as well as RNA/DNA sequences are quality controlled. The latter ones are then translated
into protein sequences. The second steps includes descriptor encoding and interpolation. Next, the drug resistance/tropism is predicted on a per
sequences level. Finally, a clinical report is generated
A comparison between the prediction servers SHIVA,
geno2pheno (resistance and coreceptor), HIVdb, and
WebPSSM can be found in Table 1. We compared the dif-
ferent drug classes that can be predicted, the maximum
number of sequences that can be uploaded, NGS com-
patability, run time (averaged over 10 runs), whether the
server provides a clinical report, and whether the server
provides detailed access to the predicted data. In con-
trast to geno2pheno, HIVdb, and WebPSSM, SHIVA is
able to predict NGS data directly. In our recent publica-
tions, we already demonstrated the high accuracy of our
drug resistance and tropism prediction models compared
to other state-of-the-art models, e.g., geno2pheno [4, 5]
or HIVdb [6]. Thus, we restricted the comparison of the
web-services to features of usability and applicability.
geno2phenoresistance and geno2phenocoreceptor are only
able to predict up to 8 and 50 sequences, respec-
tively, while HIVdb and WebPSSM are restricted to 500
sequences. For co-receptor prediction based on NGS data
generated with 454 pyrosequencing, geno2pheno454 can
be used as well, however the preprocessing of the data
needs to be done offline. There are also differences in
run times for the prediction of 8 protease and 50 V3
sequences, respectively. It turned out that HIVdb is the
fastest tool, followed by SHIVAwith 2.89 and 6.02 seconds
for the prediction of 8 protease sequences, respectively.
In contrast, geno2phenoresistance needs 24.37 seconds. For
the prediction of co-receptor tropism, SHIVA is slower
than geno2phenocoreceptor andWebPSSM, which is mainly
due to the internal 3D-modeling process in TCUP 2.0
[16]. Except WebPSSM, all other servers provide a clini-
cal report that can be used by the clinicans, however, the
HIVdb report is not very intuitively and thus only of lim-
ited use. Onemajor drawback of geno2pheno compared to
the other servers is the lack of detailed data access, which
is in particular important for large amounts of data.
Conclusion
SHIVA represents a novel high performing alternative for
hitherto developed drug resistance testing approaches.
Fig. 3 Clinical report: Drug resistance predictions are listed in tabular form and are graphically represented demonstrating the fraction of resistant
and susceptible, i.e., non-resistant sequences. Here, prediction results are shown for an example dataset to test resistance against Ritonavir (RTV).
48.61 % of the input protease sequences derived from Sanger sequencing have been predicted to be resistant with a sensitivity of 94.02 %
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Table 1 Comparison between different prediction servers
Server PIs NRTIs NNRTIs INIs Mat. Inh. Tropism max. # NGS Run Clinical Detailed
sequences data timea report data
t access
SHIVA + + + + + + >100,000 allb 6.02 / + +
15.22
g2p[resistance] + + + + - - 8 - 24.37 + -
g2p[coreceptor] - - - - - + 50c 454c 3.03 + -
HIVdb + + + - - + 500 - 2.89 (+) +
WebPSSM - - - - - + 500 - 7.91 - +
aaveraged over 10 runs with 8 protease and 50 V3 sequences, respectively
bdata needs to be provided in FASTA format
cUsing geno2pheno[454] it is possible to predict> 100, 000 sequences, however preprocessing of the data needs to be done offline
SHIVA allows the processing of large amounts of data
derived from high-throughput technologies [18]. More-
over, SHIVA is platform independent, easy to use and
publicly available. In future, additional prediction models
that are based on multi-label classification techniques and
structural descriptors will be incorporated. Recent stud-
ies have demonstrated that such approaches have great
potential to further improve drug resistance predictions
[19, 20]. Moreover, we will incorporate GPU-based imple-
mentations [21] of our models in the near future to speed
up the prediction of large data sets.
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